FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1157-1162 April 22, 1993 Number 16 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The lysosomal storage disease cystinosis results in renal failure at approximately 10 years of age. Although oral cysteamine therapy is recognized to preserve kidney function, the extent of renal benefit has not been determined.

Methods Between 1960 and 1992, we determined 24-hour creatinine clearances in 76 children with cystinosis during 1081 admissions to the National Institutes of Health. Seventeen children were considered to have received adequate treatment with cysteamine, since they had depletion of cystine from leukocytes and began therapy before the age of 2 years; treatment lasted a mean of 7.1 years. Thirty-two children were considered to have received partial treatment, since they had poor compliance with therapy or began treatment after the age of 2; treatment lasted a mean of 4.5 years. Twenty-seven children were followed in the era before cysteamine therapy and thus never received cysteamine.

Results Of the 27 children who never received cysteamine, 16 were followed at the National Institutes of Health until renal failure occurred; their mean (±SD) creatinine clearance was 8.0 ±4.8 ml per minute per 1.73 m² of body-surface area at a mean age of 8.3 ±1.9 years. Of the 17 children who received adequate treatment, none had renal failure; their mean creatinine clearance was 57 ±20 ml per minute per 1.73 m² at 8.3 ±3.8 years of age. The mean creatinine clearance of the children who received partial or adequate treatment with cysteamine increased with age up to the age of five years and then declined linearly with age at a normal rate. For the children who received adequate treatment, the mean creatinine clearance was predicted to reach 0 ml per minute per 1.73 m² at the age of 74 years, as compared with 20 years of age for the children who received partial treatment. With no therapy, the mean creatinine clearance reaches 0 ml per minute per 1.73 m² at 10 years of age.

Conclusions Children with cystinosis who are treated early and adequately with cysteamine have renal function that increases during the first five years of life and then declines at a normal rate. Patients with poorer compliance and those who are treated at an older age do less well.

Source Information

From the Section on Human Biochemical Genetics, Human Genetics Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md.

Address reprint requests to Dr. Gahl at Bldg. 10, Rm. 9S-242, NICHD, NIH, Bethesda, MD 20892.

Full Text of this Article

This article has been cited by other articles:

• Connor, K, Lennon, R, McGraw, M E, Coward, R J M (2008). A fair reason for failing to thrive. EDUCATION AND PRACTICE 93: 50-57 [Full Text]  
• Servais, A., Moriniere, V., Grunfeld, J.-P., Noel, L.-H., Goujon, J.-M., Chadefaux-Vekemans, B., Antignac, C. (2008). Late-Onset Nephropathic Cystinosis: Clinical Presentation, Outcome, and Genotyping. CJASN 3: 27-35 [Abstract] [Full Text]  
• Gahl, W. A., Balog, J. Z., Kleta, R. (2007). Nephropathic Cystinosis in Adults: Natural History and Effects of Oral Cysteamine Therapy. ANN INTERN MED 147: 242-250 [Abstract] [Full Text]  
• Ueda, M., O'Brien, K., Rosing, D. R., Ling, A., Kleta, R., McAreavey, D., Bernardini, I., Gahl, W. A. (2006). Coronary Artery and Other Vascular Calcifications in Patients with Cystinosis after Kidney Transplantation. CJASN 1: 555-562 [Abstract] [Full Text]  
• Middleton, R., Bradbury, M., Webb, N., O'Donoghue, D., Van't Hoff, W. (2003). Cystinosis. A clinicopathological conference. 'From toddlers to twenties and beyond' Adult-Paediatric Nephrology Interface Meeting, Manchester 2001. Nephrol Dial Transplant 18: 2492-2495 [Full Text]  
• Tsilou, E T, Thompson, D, Lindblad, A S, Reed, G F, Rubin, B, Gahl, W, Thoene, J, Del Monte, M, Schneider, J A, Granet, D B, Kaiser-Kupfer, M I (2003). A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br. J. Ophthalmol. 87: 28-31 [Abstract] [Full Text]  
• Kleta, R., Gahl, W. A. (2002). Cystinosis: Antibodies and Healthy Bodies. J. Am. Soc. Nephrol. 13: 2189-2191 [Full Text]  
• Gahl, W. A., Thoene, J. G., Schneider, J. A. (2002). Cystinosis. NEJM 347: 111-121 [Full Text]  
• Rupar, C A., Matsell, D., Surry, S., Siu, V. (2001). A G339R mutation in the CTNS gene is a common cause of nephropathic cystinosis in the south western Ontario Amish Mennonite population. J. Med. Genet. 38: 615-616 [Full Text]  
• Anikster, Y., Lacbawan, F., Brantly, M., Gochuico, B. L., Avila, N. A., Travis, W., Gahl, W. A. (2001). Pulmonary Dysfunction in Adults With Nephropathic Cystinosis. Chest 119: 394-401 [Abstract] [Full Text]  
• Chang, M. H.Y., Bindloss, C. A., Grabowski, G. A., Qi, X., Winchester, B., Hopwood, J. J., Meikle, P. J. (2000). Saposins A, B, C, and D in Plasma of Patients with Lysosomal Storage Disorders. Clin. Chem. 46: 167-174 [Abstract] [Full Text]  
• Gibson, X. A., Shartava, A., McIntyre, J., Monteiro, C. A., Zhang, Y., Shah, A., Campbell, N. F., Goodman, S. R. (1998). The Efficacy of Reducing Agents or Antioxidants in Blocking the Formation of Dense Cells and Irreversibly Sickled Cells In Vitro. Blood 91: 4373-4378 [Abstract] [Full Text]  
• Gahl, W. A. (1997). Consultation with the Specialist: Nephropathic Cystinosis. Pediatr. Rev. 18: 302-304 [Full Text]  
• Meikle, P. J., Brooks, D. A., Ravenscroft, E. M., Yan, M., Williams, R. E., Jaunzems, A. E., Chataway, T. K., Karageorgos, L. E., Davey, R. C., Boulter, C. D., Carlsson, S. R., Hopwood, J. J. (1997). Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin. Chem. 43: 1325-1335 [Abstract] [Full Text]  
• Soohoo, N., Schneider, J. A., Kaplan, R. M. (1997). A Cost-Effectiveness Analysis of the Orphan Drug Cysteamine in the Treatment of Infantile Cystinosis. Med Decis Making 17: 193-198 [Abstract]  
• Cherqui, S., Kalatzis, V., Trugnan, G., Antignac, C. (2001). The Targeting of Cystinosin to the Lysosomal Membrane Requires a Tyrosine-based Signal and a Novel Sorting Motif. J. Biol. Chem. 276: 13314-13321 [Abstract] [Full Text]